Context Therapeutics Inc (NASDAQ:CNTX) — Market Cap & Net Worth
Market Cap & Net Worth: Context Therapeutics Inc (CNTX)
Context Therapeutics Inc (NASDAQ:CNTX) has a market capitalization of $33.82 Million ($33.82 Million) as of September 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23456 globally and #5106 in its home market, demonstrating a 0.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Context Therapeutics Inc's stock price $0.37 by its total outstanding shares 91879177 (91.88 Million). Also see CNTX total asset value for a full breakdown of the balance sheet.
Context Therapeutics Inc Market Cap History: 2021 to 2026
Context Therapeutics Inc's market capitalization history from 2021 to 2026. Data shows change from $244.40 Million to $33.82 Million (-41.42% CAGR). Also see CNTX cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Context Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.00% | #671 of 976 |
|
NASDAQ Composite
IXIC
|
$42.00 Trillion | 0.00% | #2211 of 3165 |
Weight: Context Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Context Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Context Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CNTX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CNTX by Market Capitalization
Companies near Context Therapeutics Inc in the global market cap rankings as of September 20, 2026. Review CNTX tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Context Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Context Therapeutics Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Context Therapeutics Inc's market cap moved from $244.40 Million to $ 33.82 Million, with a yearly change of -41.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $33.82 Million | -74.96% |
| 2025 | $135.06 Million | +40.00% |
| 2024 | $96.47 Million | -7.08% |
| 2023 | $103.82 Million | +73.39% |
| 2022 | $59.88 Million | -75.50% |
| 2021 | $244.40 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Context Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.82 Million USD |
| MoneyControl | $33.82 Million USD |
| MarketWatch | $33.82 Million USD |
| marketcap.company | $33.82 Million USD |
| Reuters | $33.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the de… Read more